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Background
Since high levels of immune activation are predictive of
progressive HIV disease, host immunoregulatory factors
that blunt immune activation may contribute to delayed
disease progression. Heme oxygenase-1 (HO-1), the rate-
limiting enzyme in heme catabolism, is a potent anti-
inflammatory protein that may represent one such factor.
Methods
We hypothesize that efficient up-regulation of HO-1 in
response to HIV-1 infection is associated with more favo-
rable clinical outcomes. To address this hypothesis, we
conducted a candidate genotyping study of HO-1 pro-
moter polymorphisms that are known to influence the
magnitude and rapidity of HO-1 gene expression: a mic-
rosatellite (GT)n repeat and two single nucleotide poly-
morphisms (-1135 A/G) and (-413 A/T). Specific alleles of
these genes have previously been shown to favor
enhanced  HO-1  gene expression and to correlate with
favorable outcomes in non-HIV inflammatory diseases.
Two patient groups were identified from the HIV-1
SCOPE cohort: elite controllers with no detectable
viremia (n = 47) and non-controllers with viral loads >
10,000 (n = 218) in the absence of HAART.
Results
There was an enrichment of the HO-1 (-1135A) allele in
Caucasian elite controllers compared to non-controllers
(p < 0.009). We also observed that, among elite control-
lers, there was an association between the presence of the
protective short (GT)=26 microsatellite repeat and lower
levels of CD8+ T cell activation, as measured by surface
staining of CD38 (p = 0.049). Haplotype analysis revealed
a statistically significant enrichment of a specific haplo-
type [-1135(G), -413(A), GT>26] in the non-controller
cohort (p = 0.04).
Conclusion
Our study demonstrates that Caucasian HIV-1 patients
who maintain low levels of immune activation and con-
trol viral loads to undetectable levels are more likely to
possess HO-1 promoter polymorphisms that favor
enhanced  HO-1  gene expression. These results suggest
that efficient induction of HO-1 may play a role in limit-
ing HIV-induced immune activation in the host, resulting
in less immune dysfunction and better clinical outcomes.
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